Immunotherapy of acute myeloid leukemias: Development of vaccines and cell therapy approaches;Immunothérapie des leucémies aiguës myéloï des: Développement d'approches vaccinales utilisant des cellules dendritiques dérivées de blastes leucémiques

Bulletin du Cancer

Volumn 90, Issue 8-9, 2003, Pages 751-757

  Mohty, Mohamad ^a   Gaugler, Béatrice ^a   Calmels, Boris ^a   Blaise, Didier ^a   Vey, Norbert ^a   Chabannon, Christian ^a   Olive, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Acute myeloblastic leukemia; Immunotherapy

Indexed keywords

CANCER VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CELL DIFFERENTIATION; DENDRITIC CELL; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; ONTOGENY; REVIEW; SCALE UP; VACCINATION; VALIDATION PROCESS;

ACUTE DISEASE; CANCER VACCINES; DENDRITIC CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LEUKEMIA, MYELOID; REMISSION INDUCTION;

EID: 0141887621     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. Reiffers J, Stoppa AM, Attal M, Miehallet M, Marit G, Blaise D, et al. Allogeneic vs. autologous stem cell transplantation vs. chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-82.
3. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-8 (erratum: Blood 1989; 74: 180).
4. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-34.
5. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; ii: 175-8.
6. Bacigalupo A, Virale V, Corvo R, Batra S, Lampatelli T, Gualandi F, et al. The combined effect of total body irradiation (TBI) and cyclospotin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108: 99-104.
7. Kolb HJ, Schattenbetg A, Goldman JM, Hertenstrein B, Jacobsen N, Atcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group of Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 56: 2041-50.
8. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralr S, Champlin S, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-44.
9. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9.
10. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosri A, et al. Effectiveness of donor natural killer cell alloreactiviry in mismatched hemaropoietic transplants. Science 2002; 295: 2097-100.
11. Farag SS, Fehniger TA, Ruggeri L, Vdardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-47.
12. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
14. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2: 585-9.
15. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-61.
16. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
17. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101-11.
18. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nature Med 1999; 5: 919-23.
19. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
20. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28-35.
21. Wu CY, Wang K, McDyer JF, Seder RA. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998; 161: 2723-30.
22. Rea D, van Kooten C, van Meijgaarden KE, Ottenhoff TH, Melief CJ, Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000; 95: 3162-7.
23. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192: 219-26.
24. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polatization. Nature Immunol 2000; 1: 305-10.
25. Bell D, Young JW, Bancheteau J. Dendritic cells. Adv Immunol 1999; 72: 255-324.
26. Thurnher M, Radmayr C, Ramoner R, Ebnet S, Bock G, Klocket H, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996; 68: 1-7.
27. Chaux P, Moutet M, Faivre J, Martin F, Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996; 74: 975-83.
28. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150: 641-51.
29. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72: 619-24.
30. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989; 63: 496-503.
31. Fox SB, Jones M, Dunnill MS, Gatter KC, Mason DY. Langerhans cells in human lung tumours: an immunohistological study. Histopathology 1989; 14: 269-75.
32. Schroder S, Schwarz W, Rehpenning W, Loning T, Bocker W. Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol 1988; 89: 295-300.
33. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990; 66: 2012-6.
34. Nomori H, Watanabe S, Nakajima T, Shimosato Y, Kameya T. Histiocytes in nasopharyngeal carcinoma in relation to prognosis. Cancer 1986; 57: 100-5.
35. Viac J, Schmitt D, Claudy A. CD40 expression in epidermal tumors. Anticancer Res 1997; 17: 569-72.
36. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-103.
37. Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langethans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 1998; 161: 4842-51.
38. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8* T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634-42.
39. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med 2001; 7: 1339-46.
40. Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballerie XN, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001; 98: 3750-6.
41. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-8.
42. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230-7.
43. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 1999; 29: 2567-78.
44. Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780-6.
45. Robinson SP, English N, Jaju R, Kearney L, Knight SC, Reid CD. The in-vitro generation of dendritic cells from blast cells in acute leukaemia. Br J Haematol 1998; 103: 763-71.
46. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999; 94: 2048-55.
47. Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R, Falkenburg JH. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 2000; 61: 565-74.
48. Oehler L, Berer A, Kollars M, Keil F, Konig M, Waclavicek M, et al. Culture requirements for induction of dendritic cell differentiation in acute myeloid leukemia. Ann Hematol 2000; 79: 355-62.
49. Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 2000; 18: 139-47.
50. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by « leukemic dendritic cells » derived from blast cells in acute myeloid leukemia. Blood 2001; 97: 2764-71.
51. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001; 15: 246-55.
52. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res 1999; 18: 485-92.
53. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-34.
54. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
55. + cytotoxic T- lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-93.
56. Mohty M, Isnardon D, Blaise D, Mozziconacci MJ, Lafage-Pochitaloff M, Briere F, et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 2002; 16: 2267-74.
57. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-8.
58. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engteman EG, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myetoma: a feasibility study. Blood 1999; 93: 2411-9.
59. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80.
60. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997; 32: 272-8.
61. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166: 4254-9.
62. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-82.
63. Nestle FO, Alijagic S, Gilliet M, Sun Y, Gtabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-32.
64. + progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-8.
65. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24: 66-78.
66. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
67. + hematopoietic progenitor cells. Int J Cancer 2000; 86: 385-92.
68. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-8.
69. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Btossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2000; 6: 332-6.
70. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brennet MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res 1999; 23: 549-57.
71. Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15-29.
72. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002; 62: 2861-8.
73. Barratt-Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164: 2487-95.
74. + hematopoietic progenitor cells. Cancer Immunol Immunother 1999; 48: 118-22.